Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC)

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Tuberous SclerosisAngiofibromaHypomelanotic MaculePlaque

Interventions

DRUG

NPC-12G gel

NPC-12G gel is administered topically twice a day for 12 weeks

DRUG

Placebo gel

NPC-12G gel placebo is administered topically twice a day for 12 weeks

Trial Locations (1)

Graduate School of Medicine, Osaka University, Suita, Osaka